MESO vs. ABOS, AGEN, SCLX, BDTX, CGEN, CRDF, STRO, ELEV, VXRT, and GRTS
Should you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Acumen Pharmaceuticals (ABOS), Agenus (AGEN), Scilex (SCLX), Black Diamond Therapeutics (BDTX), Compugen (CGEN), Cardiff Oncology (CRDF), Sutro Biopharma (STRO), Elevation Oncology (ELEV), Vaxart (VXRT), and Gritstone bio (GRTS). These companies are all part of the "biological products, except diagnostic" industry.
Mesoblast (NASDAQ:MESO) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, community ranking, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.
Mesoblast received 385 more outperform votes than Acumen Pharmaceuticals when rated by MarketBeat users. Likewise, 70.83% of users gave Mesoblast an outperform vote while only 64.29% of users gave Acumen Pharmaceuticals an outperform vote.
Mesoblast presently has a consensus price target of $13.67, indicating a potential upside of 172.79%. Acumen Pharmaceuticals has a consensus price target of $12.25, indicating a potential upside of 202.47%. Given Acumen Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Acumen Pharmaceuticals is more favorable than Mesoblast.
Acumen Pharmaceuticals has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Acumen Pharmaceuticals had 5 more articles in the media than Mesoblast. MarketBeat recorded 18 mentions for Acumen Pharmaceuticals and 13 mentions for Mesoblast. Acumen Pharmaceuticals' average media sentiment score of 0.71 beat Mesoblast's score of 0.27 indicating that Acumen Pharmaceuticals is being referred to more favorably in the news media.
Mesoblast has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500. Comparatively, Acumen Pharmaceuticals has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.
1.4% of Mesoblast shares are held by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 7.5% of Acumen Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Acumen Pharmaceuticals has a net margin of 0.00% compared to Mesoblast's net margin of -1,061.43%. Mesoblast's return on equity of -16.32% beat Acumen Pharmaceuticals' return on equity.
Summary
Acumen Pharmaceuticals beats Mesoblast on 10 of the 17 factors compared between the two stocks.
Get Mesoblast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Mesoblast Competitors List
Related Companies and Tools